Overview
International law firm McDermott Will & Emery represented private equity firm Iron Path Capital in its acquisition of Gateway Chemicals Ltd. (d/b/a Aldon Corporation), a New York-based private-label manufacturer and distributor to the healthcare, life science and STEM education end markets. Aldon will serve as the first investment under VION Biosciences LLC, Iron Path Capital’s go-forward roll-up platform in the life science sector led by life science industry veteran and former Avantor executive, Mark Thornton. Aldon is a producer of specialty, private-label lab chemicals and chemical contract manufacturing solutions in life science applications, including blending and repackaging capabilities and kitting solutions for healthcare and STEM education systems.
The McDermott team was led by Hunter Sharp, Krist Werling and Marisa Young and included Josh Cohrs, Jennifer Mikulina, Tom DaMario, Jeff Holdvogt, Alex Ruiz, Dino Ilievski, Jacob Hollinger, Brian Mead, Adam Marks and Abby Higgins.
David Ivill and Krist Werling are the relationship partners for Iron Path Capital.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
